Randomized Phase III Study of FOLFOX Alone or With Pegilodecakin as Second-Line Therapy in Patients With Metastatic Pancreatic Cancer That Progressed After Gemcitabine (SEQUOIA)
J. Randolph Hecht, Sara Lonardi, Johanna Bendell, Hao Wen Sim, Teresa Macarulla, Charles D. Lopez, Eric van Cutsem, Andres J. Muñoz Martin, Joon Oh Park, Richard Greil, Hong Wang, Rebecca R. Hozak, Ivelina Gueorguieva, Yong Lin, Sujata Rao, Baek Yeol Ryoo
Dive into the research topics of 'Randomized Phase III Study of FOLFOX Alone or With Pegilodecakin as Second-Line Therapy in Patients With Metastatic Pancreatic Cancer That Progressed After Gemcitabine (SEQUOIA)'. Together they form a unique fingerprint.